baericidal activity of cefamandole against strain 55. These in vitro effects of clindmycin on strain 55 that were related to prevention of derepression oflatamase were confirmed in vivo with an animal model of infection. These results indicate that in some strains, clindamycin can specifically prevent derepression of 4-lactamases without inhibiting growth. Such a selective effect may provide a new approQach for the enhancement of the antibacteril activity'of certain 3-lactam antibiotics.
Certain genera of inonfastidious, gram-negative bacilli possess inducible P-lactamases which, when derepressed, are responsible for resistance to a variety of 1-lactam antibiotics (19) . This derepression may occur via oneof two mechanisms: (i) spontaneous mutation of the wild type to a stably derepresaed -state or (ii) reversible derepression of the wild type by a 1-lactamase inducer (9, 10, 12, 19) . The former mechanism has been shown to be responsible for the, emergence of multiple ,B-lactam resistance during therapy with new cephalosporins (3, 17, 20) ,> whereas the latter mechanism has been shown to be responsible for the antagonism of 1-lactai drugs by cefo,.itin (8,, 11, '2, 27 First , it has been shown to inhibit synthesis of certain proteins in gram-positive bacteria without affecting others (5, 6, 16, 23 possessing cefoxitin-inducible P-lactamases (10, 17, 20, 22) . The stable derepressed mutant of Enterobacter cloacae 55 was selected in the laboratory and has been described in detail previously (10 24, 1983 suspended in broth (10' CFU/ml) containing the antibiotics and incubated at 37°C in air for 24 h. At various time points, samples were removed and the number of viable CFU per milliliter was determined by agar dilution plate counts performed in duplicate. The ability of cefoxitin to antagonize cefamandole was evaluated in a disk approximation test previously described in detail (21, 22) . A low-concentration cefoxitin disk was prepared for this test by dipping sterile disks into a solution of 30 ,ug of cefoxitin per ml.
-Lactmasc assays. 1-Lactamase assays were performed with a spectrophotometric assay in which whole cells were used as described previously (21) . Enzymes were induced (derepressed) in wild-type cells by growing them overnight on Mueller-Hinton agar containing 25 Fg of cefoxitin per ml. The influence of other antibiotics on the derepression of 1B-lactamases by cefoxitin was determined by incorporating the antibiotics into the agar with cefoxitin during the induction period. The concentrations of antibiotics used in combination with cefoxitin did not inhibit the growth of the organisms (as determined by the agar dilution susceptibility tests described above). Differences in ,B-lactamase activity of >2 standard deviations (10 nmol/109 cells) were considered significant.
f-Galacs assays. Strains were grown overnight on Mueller-Hinton agar containing 20 ,g of clindamycin per ml with and without 0.5 mM isopropylthio-1-galactoside. Cells were harvested from the plates after incubation, and crude cell-free sonicated extracts were prepared as described before (9) . The protein content of these extracts was determined by the method of Lowry et al. (14) . 3-Galactosidase activity of the extracts was determined by the method of Wallenfels (26) , in which the cleavage of o-nitro- Animal studies. The ability of clindamydin to alter the in vivo efficacy of cefamandole was determined with an animal infection model described previously (8) . Male CF-1 mice weighing 20 to 25 g each were infected intraperitoneally with one 100% lethal dose of E. cloacae 55. Cefamandole nafate was administered intramuscularly at five different dosages to groups of mice (10 mice per group) at 1 and 3.5 h postchallenge. Clindamycin phosphate (200 mg/kg of body weight) was administered intramuscularly to some animals at 0.5 h before, at the time of, and 1 and 3.5 h after challenge. This dose schedule for clindamycin was chosen to produce consistently high serum levels (18 to 25 Fg/ml; data on ifie, The Upjohn Co.) of the biologically active drug throughout the test period. Although this regimen did produce diarrhea in all animals, it was not fatal and lasted only 36 h. Sodium cefoxitin (3.12 mg/kg) was also administered at the time of challenge to some animals. This amoint was chosen because it was the lowest, nonprotective dose of cefoxitin found in preliminary tests to be capable of antagonizing the efficacy of cefamandole. The influence of clindamycin on the efficacy of cefamandole and on the ability of cefoxitin to antagonize cefamandole was determined by calculating the cefamandole dose required to protect 50%1o of the animals from death at 48 h postchallenge. The 95% confidence levels were also determined (13) .
RESULTS
Derepression (induction) of 1-lactamases in wild-type strains. Initial studies were performed with E. cloacae 55 to determine the minimal concentration of clindamycin required to significantly inhibit the derepression of ,B-lactamase by cefoxitin. Clindamycin at 2 ,ug/ml did not affect derepression; 10 ,ug/ml diminished derepression by 17%, and 20 ,ug/ml completely prevented derepression. Therefore, the ability of clindamycin (20 pug/ml) to affect cefoxitin derepression of ,-lactamases in three other strains ofEnterobacter spp. and four P. aeruginosa strains was determined. Clindamycin diminished the derepression of ,B-lactamase in one other Enterobacter strain (91) and one of the four Pseudotnonas strains (166) ( Table 1) . Cefoxitin at 25 ,ug/ml did not derepress 3-lactamase in P. aeruginosa L21.
However, derepression did occur when 100 p,g of cefoxitin per ml was utilized. Clindamycin (20 ,ug/ml) did not affect this derepression.
Since E. cloacae 55 was most susceptbile to the effects of clindamycin, this strain was used in subsequent studies designed to further assess the influence of clindamycin on derepression of ,B-lactamases. In the first set of tests, the ability of clindamycin (MIC, >64 Fg/ml) to diminish derepression of 1-lactamase by cefoxitin was compared with those of (i) pirlimycin (U-57930E, a clindamycin derivative) and erythromycin, two other inhibitors of protein synthesis lacking intrinsic activity against E. cloacae 55 on September 20, 2017 by guest http://aac.asm.org/ Downloaded from (MIC, >64 ,ug/ml); (ii) chloramphenicol and tetracycline, two inhibitors of protein synthesis possessing intrinsic activity against E. cloacae 55 (MICs, 8 ,ug/ml and 2 ,ug/ml, respectively); (iii) nalidixic acid, an inhibitor of DNA synthesis (MIC, 2 tLg/ml); and (iv) rifampin, an inhibitor of DNA-dependent RNA synthesis (MIC, 32 Sxg/ml). In these tests, all antibiotics were used at a concentration which, when combined with 25 ,ug of cefoxitin per ml, did not inhibit the growth of E. cloacae 55. For antibiotics active against E. cloacae 55, this was the highest concentration that did not inhibit growth. None of the other antibiotics diminished derepression of p-lactamase in E., cloacae 55 to the extent that clindamycin did (Table 2) . Of the other six antibiotics tested, only tetracycline and rifampin diminished derepression of ,B-lactamase. However, it was diminished only slightly by these drugs, in contrast to clindamycin, which completely prevented derepression.
Since clindamycin appeared to prevent derepression of ,B-lactamase by cefoxitin in E. cloacae 55, tests were performed to determine whether it would also prevent antagonism of cefamandole by cefoxitin, as was demonstrable in disk approximation tests. These tests were performed exactly as described previously, except clindamycin (20 /ml) was incorporated into the test agar. In .these disk approximation tests, in which a low-concentration cefoxitin disk was used, ciindamycin did prevent the antagonism of cefamandole by cefoxitin. In addition, incorporation of clindamycin into the agar during standard disk diffusion susceptibility (Fig. 1) . Clindamycin alone possessed little activity, whereas cefamandole alone produced an initial bactericidal effect which was followed by regrowth of the strain. Animal studies. Since in vitro tests had shown that clindamycin could prevent derepression of g-lactamase in E. cloacae 55 and enhanced killing of this strain by cefamandole, additional tests were performed to determine whether similar effects could be demonstrated in vivo. In one series of tests, the ability of clindamycin to prevent antagonism of cefamandole by cefoxitin in vivo was evaluated. Previous studies have shown this antagonism to be due to the in vivo derepression of 1-lactamase by cefoxitin (8 this test, cefoxitin was administered at the time of challenge; clindamycin was administered 0.5 h before challenge, at the time of challenge, and 1 and 3.5 h postchallenge; and cefamandole was administered at 1 and 3.5 h postchallenge ( Table  5) . As was seen in the in vitro tests, clindamycin prevented the moderate in vivo antagonism of cefamandole by cefoxitin. In a second series of tests, the direct influence of clindamycin on the in vivo efficacy of cefamandole was determined.
In these tests, clindamycin and cefamandolk were administered as before. There was no cefoxitin administered. Clindamycin significantly enhanced the in vivo efficacy of cefamandole (Table 5) .
DISCUSSION The results of this study indicate that clindamycin is capable of diminishing derepression of P-lactamases in some gram-negative bacterial strains. In general, this characteristic was -not shared by other inhibitors of protein, RNA, or DNA synthesis when tested at concentrations that did not inhibit replication. In fact, pirlimycin, a closely related analog of clindamycin (1) , had no effect on derepression of P-lactamases.
Several previous studies have focused on the effects of protein synthesis inhibitors on 3-lactamase synthesis in bacteria. However, most of these studies involved strains intrinsically susceptible to the protein synthesis inhibitor. Michel and co-workers have shown that chloramphenicol and cephaloridine were synergistic against some Enterobacteriaceae strains (15). 
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This synergy was demonstrable only in tests with cephaloridine-resistant, chloramphenicolsusceptible strains. Antagonism usually occurred in tests with strains susceptible to both drugs. This synergy was due to the inhibition of A-lactamase synthesis by chloramphenicol and has been shown to be operative both in vitro and in vivo (15, 18) . In similar studies with Staphylococcus aureus, Michel et al. demonstrated that clindamycin diminished penicillinase production by this organism (16) . This effect, however, occurred only in tests with clindamycin-susceptible strains. Our investigation is the first to report an effect of clindamycin on 1-lactamase synthesis in nonfastidious, gram-negative bacteria.
The results obtained with E. cloacae 55 indicated that certain processes may be highly susceptible to inhibition by clindamycin, whereas others are totally unaffected. In this strain, clindamycin prevented derepression of P-lactamase under conditions that had no effect on derepression of f-galactosidase. In tests with the derepressed mutant of this strain, 55M, clindamycin had no effect on either constitutive P-lactamase synthesis or P-galactosidase derepression. Hypersusceptibility of inducible enzymes to inhibition has been previously reported by Sypherd and DeMoss (24) and Sypherd et al. (25) in studies with chloramphenicol. Although P-lactamase was not evaluated, these authors reported that the synthesis of a number of enzymes under repressor control in Escherichia coli was preferentially inhibited by chloramphenicol. Synthesis of enzymes constitutively produced were not inhibited by the drug. This preferential inhibition of inducible enzyme synthesis reported by Sypherd et al. was a much broader effect than that observed in our study, as not all inducible enzymes in E. cloacae 55 were affected by clindamycin. The molecular basis for this highly selective effect of clindamycin is unknown. However, it may involve some direct effect of clindamycin on the repressor involved with the P-lactamase operon. Identification of the repressor will be required before the clindamycin effect can be more completely explained.
The prevention of derepression of P-lactamase by clindamycin in E. cloacae 55 was associated with the inability of cefoxitin to antagonize the activity of cefamandole against this strain both in vitro and in vivo. It was also associated with an enhanced in vitro susceptibility of the strain to cefoxitin itself. This latter aspect suggests that, for Enterobacter strains with inducible P-lactamases, cefoxitin may be a self-antagonizing drug; i.e., cefoxitin derepresses a p-lactamase which is partly responsible for the high level of resistance of the organism to the drug. Since cefoxitin is a poor substrate for this enzyme, resistance may be due to the nonhydrolytic barrier mechanism that mediates resistance to nonsubstrate drugs (19) . Prevention of derepression partially restores susceptibility to the drug. The relatively low intrinsic potency and high inducer activity of cefoxitin for Enterobacter spp. may be the reasons that this selfantagonizing characteristic was so readily demonstrated.
Clindamycin enhanced the in vitro bactericidal effect of cefamandole against E. cloacae 55. Previous studies have shown that the failure of cefamandole to produce a complete bactericidal effect in vitro is due to the appearance of the stably derepressed mutant among wild-type cells (10) . Thus, the enhancement of the in vitro bactericidal effects of cefamandole may have been due to the prevention of P-lactamase derepression via mutation by clindamycin. This possibility was supported by animal studies which showed a similar enhancement of the in vivo efficacy of cefamandole by cindamycin. Previous studies have shown that the relatively low in vivo efficacy of cefamandole in the treatment of experimental infections due to Enterobacter spp. is also due to the emergence of resistant mutants (7, 8) . Although the precise mechanism responsible for this direct enhancement of cefamandole activity by clindamycin is unknown, it probably also involves some interaction with the P-lactamase operon via the repressor protein.
The ability of clindamycin to prevent derepression of P-lactamases in some bacterial strains without inhibiting their growth suggests a new approach for enhancement of the antibacterial effects of ,-lactam antibiotics. In the past, attempts to enhance the activity of 3-lactam antibiotics have been focused upon the use of inhibitors of P-lactamase function such as clavulanic acid (4 (3, 7, 8, 10-12, 17, 19-22, 27 ).
